Publication for ITGB2 and SELPLG

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	ITGB2	integrin subunit beta 2	3689			[link]
hsa	SELPLG	selectin P ligand	6404

Pubmed ID	Priority	Text
22996336	0.98	PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma
	0.96	PSGL-1 (P-selectin glycoprotein ligand-1)/selectins and ICAM-1/CD18 played an important role in macrophage-mediated myeloma cell drug resistance, as blocking antibodies against these molecules or genetic knockdown of PSGL-1 or ICAM-1 in myeloma cells repressed macrophages' ability to protect myeloma cells.
	0.56	PSGL-1 and CD18/ICAM-1, were important for MPhi/MM cell interaction to confer drug resistance to MM cells.
27892526	0.98	SELPLG and ITGB2 were common between the three diseases.
	0.96	Selectin P Ligand (SELPG), Carboxypeptidase B2 (CPB2), integrin, beta 2 (ITGB2), Protein kinase C, eta (PRKCH), Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) (RAC1), 3-phosphoinositide dependent protein kinase-1 (PDPK1), Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 (GNAI2) and Lysine (K)-specific demethylase 1A (KDM1A) were among the overexpressed while the expression of Coagulation factor II (thrombin) receptor (F2R) and protein S (alpha) (PROS1) were underexpressed.
	0.70	Selectin P Ligand (SELPLG) and Integrin beta 2 (ITGB2) are independently and significantly reported to be involved as the shared markers in the pathogenesis of PV and ET with thrombosis.
31069337	0.98	CD18, PSGL-1, and CD44s on neutrophils [white and dotted bars in Figs. S3(k) and S3(l)] were also obtained separately.
23029213	0.97	PSGL-1, LFA-1, and Mac-1 on neutrophils by flow cytometry.
	0.96	PSGL-1 and LFA-1).
	0.80	PSGL-1 (Figure 3A) and LFA-1 (Figure 3B) on neutrophils from both patient groups and from healthy volunteers was not significantly different after inducing anesthesia, following protamine administration, and 24 hours after the end of the surgical procedure.
10791984	0.96	PSGL-1, whereas incubation of neutrophils with anti-CD18 had no effect (Fig. 5).
	0.94	PSGL-1, but not by anti-CD18 antibodies.
	0.91	PSGL-1, whereas the mAb against CD18 had no effect.
9091586	0.96	CLA+/CD34+ cells showed a three- to fivefold higher expression of the beta2-integrins LFA-1 (CD11a/CD18) and Mac-1/C3bi (CD11b/CD18), and a 1.5-fold higher expression of the beta1-integrins VLA-4 (CD49d/CD29) and VLA-5 (CD49e/CD29) as compared with CLA-/CD34+ cells (Fig. 1).
29353325	0.96	PSGL-1 occurs within mutual lipid raft domains to mediate signalling to Src family kinases and trigger LFA-1 (alphaLbeta2, CD11a/CD18) integrin activation (Stadtmann et al.).
20169105	0.95	CD18, CD162, CD44, PMN placed in 3 mum pore size inserts with 10 mug/mL of mouse anti-human CD44 monoclonal antibody, 10 mug/mL of mouse anti-human CD162 monoclonal antibody and 10 mug/mL of mouse anti-human CD18 monoclonal antibody.
	0.74	CD162 monoclonal antibody and 10 mug/mL of mouse anti-human CD18 monoclonal antibody in the medium (HT-29 + AbCocktail), FaDu (FaDu), FaDu with the Ab Cocktail (FaDu + AbCocktail), and HMVEC previously treated with 10 U/mL of human recombinant IL-1beta for 5 hours (HMVEC + IL-1B) and incubated at 37 C for 30 minutes.
22271244	0.95	P-selectin glycoprotein ligand (PSGL)-1, L-selectin (on human and not mouse), E-selectin ligand (ESL)-1 (on mouse and not human), CD44, and alphaMbeta2 integrin (CD11b/CD18, Mac-1).
	0.92	PSGL-1, CD44 and other ESLs under well defined conditions of shear stress in order to directly correlate with PMN activation as detected by Ca2+ flux, assembly of phospho-MAP and Src kinases, and activated CD18.
25616042	0.93	PSGL-1 and the integrin LFA-1 were not decreased with IVIG in our study and were previously reported to be decreased with IVIG, but on non-selected leukocytes or only on mononuclear cell populations, respectively.
	0.72	PSGL-1 and CD44 and can mediate Mac-1 activation in pain crisis, it is unlikely that ESL-1 expression would change after IVIG treatment.
23690477	0.92	integrin beta2 and PSGL-1/P-selectin during monocyte adherence.
	0.91	PSGL-1 and the beta2 integrin Mac-1.
12810688	0.90	PSGL-1, CD62L, CD18, CD11a, CD11b, CD11c, very late antigen 4 (VLA-4), ICAM-1, CD31, CD44, CD32, CD64, and HLA-DR, intermediate CXCR1, and low or undetectable CCR3, CCR5, CXCR5, and CX3CR1 levels (Fig. 1, C and D, and unpublished data).
31928630	0.90	CD18, CD54, CD162), members of tumor necrosis factor receptor family (CD262, CD270), and an integrin-associated protein CD47.
25699046	0.85	PSGL-1) is phosphorylated by Src-family kinase (SFK), and leads to Mac-1 (alphaMbeta2) activation.